argenex SE $ARGX Stock Holdings Lifted by Morse Asset Management Inc

Morse Asset Management Inc increased its stake in argenex SE (NASDAQ:ARGX – Free Report) by 69.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,282 shares of the company’s stock after purchasing an additional 934 shares during the period. Morse Asset Management Inc’s holdings in argenex were worth $2,188,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ARGX. West Family Investments Inc. lifted its position in argenex by 17.6% during the third quarter. West Family Investments Inc. now owns 440 shares of the company’s stock worth $422,000 after purchasing an additional 66 shares during the period. Hantz Financial Services Inc. grew its stake in argenex by 2.1% during the third quarter. Hantz Financial Services Inc. now owns 2,874 shares of the company’s stock worth $2,756,000 after buying an additional 58 shares in the last quarter. Harbour Investments Inc. increased its holdings in argenex by 966.7% in the 3rd quarter. Harbour Investments Inc. now owns 64 shares of the company’s stock valued at $62,000 after buying an additional 58 shares during the period. Optas LLC increased its holdings in argenex by 4.6% in the 3rd quarter. Optas LLC now owns 250 shares of the company’s stock valued at $240,000 after buying an additional 11 shares during the period. Finally, Allworth Financial LP increased its holdings in argenex by 19.7% in the 3rd quarter. Allworth Financial LP now owns 170 shares of the company’s stock valued at $158,000 after buying an additional 28 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

NASDAQ:ARGX opened at $960.04 on Monday. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75. The stock’s 50-day simple moving average is $923.87 and its 200 day simple moving average is $860.78. The firm has a market capitalization of $60.38 billion, a PE ratio of 33.50, a price-to-earnings-growth ratio of 0.89 and a beta of 0.48.

argenex (NASDAQ:ARGX – Get Free Report) last issued its earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. On average, analysts anticipate that argenex SE will post 28.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on ARGX. Barclays restated a “buy” rating on shares of argenex in a research report on Monday, September 7th. HC Wainwright increased their price target on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Royal Bank Of Canada reduced their price target on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 20th. JPMorgan Chase & Co. reissued a “buy” rating on shares of argenex in a research note on Wednesday, August 5th. Finally, UBS Group upgraded shares of argenex from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $960.00 to $1,400.00 in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,155.24.

Read Our Latest Analysis on argenex

argenex Company Profile

(Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

Recommended Stories

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).

Institutional Ownership by Quarter for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.